Evacetrapib + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cardiovascular Diseases
Conditions
Cardiovascular Diseases
Trial Timeline
Oct 1, 2012 → Jul 1, 2016
NCT ID
NCT01687998About Evacetrapib + Placebo
Evacetrapib + Placebo is a phase 3 stage product being developed by Eli Lilly for Cardiovascular Diseases. The current trial status is terminated. This product is registered under clinical trial identifier NCT01687998. Target conditions include Cardiovascular Diseases.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02260635 | Phase 3 | Terminated |
| NCT01687998 | Phase 3 | Terminated |
Competing Products
20 competing products in Cardiovascular Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dulaglutide + Placebo | Eli Lilly | Phase 3 | 77 |
| raloxifene + placebo | Eli Lilly | Phase 3 | 77 |
| Evacetrapib | Eli Lilly | Phase 1 | 33 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| Prasugrel (CS-747) + Clopidogrel | Eli Lilly | Phase 2 | 52 |
| Rosuvamibe + Monorova | Yuhan | Approved | 85 |
| Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin | Yuhan | Approved | 85 |
| Rosuvamibe + Monorova | Yuhan | Approved | 85 |
| Prasugrel (Crushed tablets) + Prasugrel (Integral tablets) | Daiichi Sankyo | Approved | 85 |
| Lexiscan | Astellas Pharma | Phase 2 | 52 |
| mirabegron + tamsulosin | Astellas Pharma | Phase 1 | 33 |
| TRC150094 | Torrent Pharmaceuticals | Phase 1/2 | 41 |
| Lorcaserin hydrochloride + Placebo | Eisai | Approved | 85 |
| Lepodisiran Sodium + Placebo | Eli Lilly | Phase 3 | 77 |
| Retatrutide + Placebo | Eli Lilly | Phase 3 | 77 |
| Empagliflozin + Placebos | Eli Lilly | Approved | 85 |
| Placebo + AZD0780 | AstraZeneca | Phase 2 | 52 |
| Risk of low dose aspirin discontinuation | AstraZeneca | Pre-clinical | 23 |
| Midazolam + AZD5718 | AstraZeneca | Phase 1 | 33 |
| 14C]AZD4831 Oral Solution | AstraZeneca | Phase 1 | 33 |